Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Perou

Showing results (371-380 of 476) with videos related to

Pageof 48
Sort By:
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Nature|February 8, 2018
Asparagine bioavailability governs metastasis in a model of breast cancerSimon R V Knott, Elvin Wagenblast, Showkhin Khan, et al.
Plos Medicine|July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinomaJeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Nature|April 6, 2018
Erratum: Asparagine bioavailability governs metastasis in a model of breast cancerSimon R V Knott, Elvin Wagenblast, Showkhin Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2018
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined ClassificationIsabel Echavarria, Sara López-Tarruella, Antoni Picornell, et al.
Plos Medicine|December 30, 2006
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignanciesDavid S Shames, Luc Girard, Boning Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateKimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.
Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.
Pageof 48

Showing results (371-380 of 476) with videos related to

Sort By:
Pageof 48
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Nature|February 8, 2018
Asparagine bioavailability governs metastasis in a model of breast cancerSimon R V Knott, Elvin Wagenblast, Showkhin Khan, et al.
Plos Medicine|July 21, 2010
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinomaJeran K Stratford, David J Bentrem, Judy M Anderson, et al.
Nature|April 6, 2018
Erratum: Asparagine bioavailability governs metastasis in a model of breast cancerSimon R V Knott, Elvin Wagenblast, Showkhin Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2018
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined ClassificationIsabel Echavarria, Sara López-Tarruella, Antoni Picornell, et al.
Plos Medicine|December 30, 2006
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignanciesDavid S Shames, Luc Girard, Boning Gao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateKimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.
Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.
Pageof 48